Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT05256381
Title A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors SOTIO Biotech AG

lung non-small cell carcinoma

skin squamous cell carcinoma

prostate cancer

ovarian cancer

castration-resistant prostate carcinoma

hepatocellular carcinoma

colorectal cancer


Pembrolizumab + SOT101

Age Groups: adult | senior
Covered Countries ESP

No variant requirements are available.